Loading
Medicinal chemist who led the discovery of the proteasome inhibitor bortezomib and now heads Stand Up To Cancer as President and CEO.
Julian Adams, PhD, is President and CEO of Stand Up To Cancer, the US charity that funds collaborative 'Dream Team' cancer research. A drug-discovery scientist, he led the development of the proteasome inhibitor bortezomib (Velcade), a cornerstone therapy in multiple myeloma. He joined SU2C in July 2023 and was subsequently promoted to President and CEO, according to the organisation's leadership page.
| Title | Journal | Year |
|---|---|---|
| The development of proteasome inhibitors as anticancer drugs | Cancer Cell | 2004 |
| Development of the Proteasome Inhibitor Velcade™ (Bortezomib) | Cancer Investigation | 2004 |
| Development of the Proteasome Inhibitor PS-341 | The Oncologist | 2002 |
Shares The oncologist and the tags leadership, drug development.
Shares The oncologist and the tag leadership.
Shares Stand Up To Cancer and the tag leadership.
Shares The oncologist and the tag leadership.
Shares the tags leadership, research funding.
Shares the tags leadership, research funding.
Shares the tags leadership, research funding.
Shares the tags leadership, research funding.